Through enhanced diagnostic, disease prevention and tailored treatments, personalized healthcare holds great promise for each of us. Research in this field was long hindered by technical, interoperability, ethical and legal challenges, which prevented access to a wealth of consented biomedical data from patients. SIB has played a key role in coordinating efforts on the national level, and establishing the Swiss infrastructure which is now boosting research in this field, in which over 20 of our groups are active. We are also part of several European public-private partnerships, several of which aiming to facilitate precision medicine in cancer or diabetes. Through outreach activities, we also inform the public about the promise and challenges of precision medicine and the role of bioinformatics to enable it.
Making sense of health data to guide treatment decisions
New insights into the molecular paths leading to type 2 diabetes
In type 2 diabetes (T2D), pancreatic islet beta cells gradually become unable to...
A key ingredient of Swiss precision oncology: SVIP-O goes live
Nowadays in Switzerland, most cancerous tumours are sequenced in order to...
Discover the world of biomedicine with the new ChromosomeWalk.ch
A new version of ChromosomeWalk offers a gateway to an entertaining ‘genome...
The SPHN fact-sheet 2020 is out
Find out about the current status of the Swiss Personalized Health Network (SPHN...
How SIB is securing sensitive data for health-related research
As part of its infrastructure activities, SIB is in charge of BioMedIT , a...
New development in the cancer diagnostics platform used at the HUG
In its latest version, the cancer diagnostics platform developed jointly by the...